Author

N. DiPrimio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Organism:C. elegans· 2 Approach:deep learning· 2 Organism:Drosophila· 2 Organism:human· 2 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

F. S. Sam· 3 shared H. Tsang· 3 shared S. Iyer· 3 shared E. O. Perlstein· 2 shared J. D. Mast· 2 shared K. Murthy· 2 shared M. Prangley· 2 shared T. P. Rodriguez· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

F. S. Sam

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Multi-Species Phenotypic Screening across Disease Models of Mucolipidosis Type IV

A. Hadjikyriacou, S. Iyer, J. D. Mast, N. DiPrimio, J. Concannon, J. Ketterman, F. Sigoillot, T. P. Rodriguez, F. S. Sam, H. Tsang, M. Prangley, J. Bilen, K. Murthy, T. A. Hartl, C. Antczak, , S. M. Canham

The paper screens a compound library across invertebrate and human models of mucolipidosis IV to identify conserved disease modifiers, finding cyclin-dependent kinase inhibition as a potential therapeutic strategy.

bioRxiv · Mar 5, 2021 · PreprintCell Biology

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG

S. Iyer, F. S. Sam, N. DiPrimio, G. Preston, J. Verhejein, K. Murthy, Z. Parton, H. Tsang, J. Lao, E. Morava, E. O. Perlstein

This paper identifies epalrestat, an existing drug, as a PMM2 enzyme activator for PMM2-CDG, showing it improves enzyme activity in patient fibroblasts.

bioRxiv · Sep 26, 2019Pharmacology & Toxicology

Drug screens of NGLY1 Deficiency worm and fly models reveal catecholamine, NRF2 and anti-inflammatory pathway activation as potential clinical approaches

S. Iyer, J. D. Mast, H. Tsang, T. P. Rodriguez, N. DiPrimio, M. Prangley, F. S. Sam, Z. M. Parton, E. Perlstein

The paper identifies drug candidates that rescue growth in NGLY1-deficient worm and fly models by targeting NRF2, anti-inflammatory pathways, and catecholamine signaling.

bioRxiv · Aug 28, 2019Pharmacology & Toxicology